Boise's obesity rate against Idaho's, Idaho Medicaid's obesity-indication exclusion, two clinics that publish full cash prices, and a shortage pattern covering nearly the whole state.
29.0% of Boise adults have obesity (CDC PLACES 2025 release, BRFSS 2023) 1, below Idaho's statewide 31.0% 2. Boise is the unusual case in this series: the city runs cooler than the state around it, not hotter.
That does not make treatment cheaper here. In a city of 237,959 inside an 844,979-person metro, with a median household income of $81,102 and 6.9% uninsured 3467, the binding constraint is that Idaho Medicaid does not pay for the obesity indication and every Boise provider publishing a price is self-pay.
Idaho Medicaid covers GLP-1 drugs like Ozempic and Mounjaro only for their type-2-diabetes indication, not for the obesity or weight-loss indication (Wegovy, Zepbound). KFF's Medicaid Coverage of and Spending on GLP-1s tracker, updated Jan. 16, 2026, lists Idaho explicitly as Not covered for obesity-indication GLP-1s under Medicaid fee-for-service: diabetes-indication coverage is a federal Medicaid Drug Rebate Program requirement, while the obesity indication remains state-optional and Idaho has opted out 13.
Every Boise-based GLP-1 provider found publishing its own pricing operates on a self-pay basis as a result, and Idaho Outreach Medicine states this outright on its own site 12. One watch item: CMS's BALANCE model, opening May 2026, would let participating states buy GLP-1s at negotiated prices for Medicaid obesity coverage; whether Idaho opts in is unresolved and should be rechecked before treating this exclusion as permanent 13.
Spa 35 Med Spa publishes full GLP-1 injection pricing: $599/month month-to-month at any phase or dosage, or a 6-month membership at 20% off tiered as Phase 1 Foundation $319/mo, Phase 2 Progression $399/mo, and Phase 3 Peak $479/mo, with a $500 early-termination fee. A $49 initiation fee covers bloodwork and labs, and the program includes an NP consultation with RN-administered or home auto-pen delivery and ongoing dosage monitoring 11.
Idaho Outreach Medicine publishes a full fee schedule for its house-call weight-loss program serving Boise and the Treasure Valley: $249 initial consult and $199 quarterly follow-up, both explicitly self-pay, since insurance does not cover this type of supervised weight-loss care. Medication is billed separately through a partner pharmacy at $120 to $200/month for semaglutide and $160 to $300/month for tirzepatide depending on dose 12.
Astra's price is national and flat: $68/month for semaglutide and $118/month for tirzepatide on 12-month plans, $816 and $1,416 billed annually, the same in every city and at every dose. There is no Boise rate and no Idaho discount.
Ada County, which contains Boise, carries active federal Health Professional Shortage Area designations in primary care, dental health, and mental health, per HRSA's Bureau of Health Workforce shortage-area data 8. Statewide, the Idaho Department of Health & Welfare reports that 98.7% of Idaho's primary-care geography, 100% of its mental-health geography, and 95.7% of its dental geography carry an active HPSA designation, so Boise, despite being Idaho's largest urban core, is not exempt from a shortage pattern that covers nearly the entire state 9. These designations are typically partial-county or facility-specific rather than one blanket score for all of Ada County 10.
HRSA's HPSA program doesn't score endocrinology or obesity medicine as a discipline, so there's no federal shortage designation specific to GLP-1 prescribing capacity. Directory data, a Healthgrades count rather than an official shortage metric, lists roughly 14 endocrinology and diabetes/metabolism specialists practicing in the Boise area, affiliated with St. Luke's Boise Medical Center and Saint Alphonsus Regional Medical Center, a modest bench for an approximately 845,000-person metro 14.
The tighter bottleneck sits at the primary-care referral layer, where Ada County's confirmed HPSA designation means the visit needed to get a referral can itself be the delay 8. Telehealth GLP-1 care routes around that referral chain by putting a licensed prescriber directly in front of the patient. See the Idaho GLP-1 overview for statewide context.
Astra treats patients in Idaho through state-licensed physicians.
Yes, in every case found. Boise's price-transparent local options run from about $120/month for low-dose compounded semaglutide (Idaho Outreach Medicine) up to $599/month for Spa 35 Med Spa's all-inclusive month-to-month plan — before the $49–$249 consult or initiation fees each clinic charges on top. Astra's national rate is $68/month for semaglutide and $118/month for tirzepatide on a 12-month plan, with no separate visit fees and no membership tiers. That's the same price whether you're in Boise or anywhere else Astra operates.
No. Idaho Medicaid covers GLP-1 drugs like Ozempic and Mounjaro only when prescribed for type 2 diabetes, not for weight loss. KFF's Medicaid GLP-1 coverage tracker lists Idaho as 'Not covered' for the obesity indication (Wegovy, Zepbound) as of its January 2026 update. That's part of why every Boise-based GLP-1 provider checked, including Idaho Outreach Medicine, operates on a self-pay basis.
Boise actually runs slightly better than its state on this measure, which is unusual for a mid-sized city. CDC PLACES puts Boise's crude obesity prevalence at 29.0% (BRFSS 2023), about two points below Idaho's statewide 31.0% for the same year. Idaho's newer statewide BRFSS figure (32.7% in 2024) widens that gap further, though there's no matching 2024 city-level release yet to confirm Boise's number moved in step.
Ada County, which contains Boise, carries an active federal Health Professional Shortage Area designation in primary care, per HRSA's Bureau of Health Workforce data. It isn't unique to Boise — Idaho's own Department of Health & Welfare reports that 98.7% of the state's primary-care geography carries the same designation, so Idaho's largest city isn't exempt from a shortage pattern covering nearly the entire state.
Yes. Astra's telehealth model is licensed across all 50 states, including Idaho, so Boise residents can complete an intake, get evaluated, and receive a prescription without an in-person visit. That matters most in a market like Ada County's, where the confirmed primary-care shortage can make the in-person referral step itself the bottleneck to starting treatment.
Last reviewed:
Educational information, not medical advice. Treatment requires evaluation by a licensed physician.